GLP-1 Legal Support
Response within one business day

Quick Case Evaluation

Find out if you qualify in 30 seconds

This field is required.
This field is required.

Free Consultation • No Fee Unless We Win

MDL 3094 • 2,900+ filings Nationwide GLP-1 counsel

Have You Suffered Serious Side Effects from a GLP‑1 Drug?

Drugs like Ozempic, Wegovy, and Mounjaro have helped many manage diabetes and weight — but for some, the cost has been devastating. If you've experienced stomach paralysis (gastroparesis), intestinal blockage (ileus), persistent vomiting, or other serious complications, you may be entitled to legal compensation.

2,914+ MDL Lawsuits
24,499+ Reported Cases
24h Response Time
Check Your Eligibility Now

Free Case Evaluation • No Fee Unless We Win

Confidential Consultation Experienced Legal Team Nationwide Service

Serious Health Risks from GLP-1 Medications

Thousands of patients have experienced severe complications from Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs. Our legal team is dedicated to helping victims seek compensation and justice.

Free Case Evaluation

No fee unless we win your case. Free consultation available.

MDL 3094: Nationwide Lawsuits Are Underway

As of December 2025, MDL No. 3094 has surpassed 2,900 filings (nearing 3,000) against Novo Nordisk and Eli Lilly, the makers of Ozempic, Wegovy, and Mounjaro.

These lawsuits allege that:

  • The drugmakers failed to warn patients of the risk of serious gastrointestinal injuries
  • Patients suffered long-term or permanent damage, including gastroparesis, bowel obstruction, pancreatitis, and more

The cases are now moving forward in federal court under Judge Gene E.K. Pratter in Philadelphia. If you've been harmed, contact us immediately for a free case evaluation and join the ongoing litigation.

Each case remains individual. The sooner you act, the better your chances of preserving your rights and medical evidence.

Critical Statistics

Recent studies and reports reveal alarming statistics about GLP-1 medication side effects.

24,499
Emergency Department Visits
10+
Deaths Reported
100+
Hospitalizations
2,914+
MDL Lawsuits

Common Side Effects Named in Lawsuits

GLP-1 medications have been linked to numerous serious health complications that can be life-altering.

Gastrointestinal Injuries

  • Gastroparesis (stomach paralysis)
  • Persistent nausea or vomiting
  • Intestinal blockage (ileus)
  • Pancreatitis

Other Potential Complications

  • Vision loss
  • Kidney dysfunction
  • Suicidal ideation or mood changes
  • Severe dehydration & malnutrition

Gastroparesis (Stomach Paralysis)

A condition where the stomach cannot empty properly, leading to severe nausea, vomiting, and abdominal pain. Many patients require surgical intervention.

Click for detailed information →

Pancreatitis

Inflammation of the pancreas that can be life-threatening. Studies show increased risk compared to other weight loss medications.

Click for detailed information →

Gallbladder Disease

Including gallstones and inflammation requiring surgical removal. Multiple patients have reported needing gallbladder removal after taking GLP-1 medications.

Click for detailed information →

Bowel Obstruction

Blockages preventing food or liquid from moving through the intestines, requiring emergency medical intervention.

Click for detailed information →

Intestinal Tissue Death

As reported in multiple cases, requiring surgical removal and permanent ileostomy. Some patients have lost parts of their large intestine.

Click for detailed information →

Kidney Problems

Including reduced kidney function and potential kidney damage, particularly concerning for long-term use.

Click for detailed information →

Optic Nerve Damage

Potential vision impairment, as alleged in recent lawsuits against manufacturers.

Click for detailed information →

Mental Health Issues

Including potential suicidal thoughts, as identified in European research and FDA monitoring.

Click for detailed information →

Legal Developments & Lawsuits

Recent MDL filings, court orders, and enforcement actions tied to GLP-1 medications. Showing the past 12 months by default. View full archive →

Dec 5, 2025

MDL Approaches ~3,000 Cases

Filing pace remains strong; NAION vision-loss claims rising alongside GI allegations.

Nov 3, 2025

2,914 Cases Filed

MDL 3094 adds 100+ cases in October, underscoring sustained momentum.

Oct 31, 2025

Court Sets 2026 Deadlines

Expert discovery due Mar 27, 2026; summary judgment Apr 16, 2026; bellwethers expected mid-2026.

Oct 1, 2025

2,809 Cases on File

September adds 133 cases as filings remain steady.

Sep 11, 2025

Lilly Seeks NAION Centralization

Motion to pull all GLP-1 NAION vision-loss suits into MDL 3094 or a parallel MDL.

Sep 6, 2025

Court Defines Allowed Claims

MDL permits NAION (optic nerve ischemia) and objectively confirmed gastroparesis claims.

Sep 2, 2025

2,676 Cases Filed

Nearly 500 new filings in August alone.

Aug 19, 2025

Gastric Emptying Study Requirement

Gastroparesis claimants must provide objective gastric emptying tests or risk exclusion.

Aug 4, 2025

Novo Nordisk Sues Compounders

Action against 12 defendants selling compounded semaglutide without FDA approval.

Aug 1, 2025

2,190 Cases Filed

Continued growth of MDL 3094 docket.

Jul 1, 2025

1,997 Cases Filed

MDL nears 2,000 filings; NAION claims begin to rise.

Apr 2025

Study: 24,499 ER Visits

Annals of Internal Medicine links semaglutide to thousands of ER visits in two years.

Sep 2024

Severe GI Injury Case

Reported intestinal tissue death and permanent ileostomy after Wegovy/Ozempic use.

Mar 2024

Initial Case Centralization

Dozens of early GLP-1 suits centralized in federal court, setting MDL groundwork.

Latest News & Research

Stay informed about the latest developments and research regarding GLP-1 medications and their potential side effects.

2025 GLP-1 MDL Milestones & Court Orders

Case counts near 3,000; court sets 2026 expert and summary-judgment deadlines with NAION claims rising.

Updated: Dec 5, 2025

Safety & Regulatory Highlights (Late 2025)

Alzheimer’s trials fail; CTAD disclosures; Australia TGA adds suicide risk warning to all GLP-1 labels.

Updated: Dec 5, 2025

Poison control calls surge as GLP-1 drugs gain popularity

Pennsylvania and New Jersey poison control centers described a steep rise in calls related to GLP-1 weight-loss drugs. Exposures at New Jersey's center jumped from 29 cases in 2021 to 189 in 2024.

Source: WHYY News, May 2025

Patients sue over alleged side effects of GLP-1 drugs

A TIME investigation highlights lawsuits filed by patients who experienced debilitating side effects while taking Ozempic, Wegovy, Mounjaro and other GLP-1 drugs.

Source: TIME Magazine, November 2024

Ozempic face and other GLP-1 side effects

UCLA Health explains that rapid weight loss from GLP-1 drugs can cause cosmetic changes dubbed "Ozempic face" along with digestive issues.

Source: UCLA Health, May 2025

Additional Research & Case Studies

Comprehensive research findings and detailed case studies documenting the impact of GLP-1 medications.

Vision Risk Research on Semaglutide (2025)

RVO risk up 1.6x, NAION odds 68.6x higher, and JAMA Ophthalmology incidence at 14.5 per 100k person-years.

Updated: Dec 3, 2025

Study Links GLP-1 Drugs to Severe Stomach Problems

Research published in the Journal of the American Medical Association found that people taking GLP-1 drugs for weight loss had a higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to those taking non-GLP-1 weight loss medications.

Source: NBC News, October 2023

Nearly 25,000 Emergency Department Visits Linked to Semaglutide

A study published in Annals of Internal Medicine revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval for weight loss.

Source: Healio Gastroenterology, April 2025

FDA Reports Multiple Deaths and Hospitalizations from Compounded Semaglutide

Approximately 10 deaths and 100 hospitalizations in the United States have been linked to use of off-brand, compounded semaglutide, according to the drug's manufacturer Novo Nordisk.

Source: Pharmacy Times, November 2024

Recent Developments

Latest updates and developments in GLP-1 litigation and research.

MDL Nears 3,000 Cases; 2026 Deadlines Set (Dec 2025)

MDL 3094 approaches 3,000 filings; court sets expert discovery for Mar 27, 2026 and summary judgment by Apr 16, 2026—bellwethers expected mid-2026.

See full MDL 2025 milestones →

Evidence & Claim Scope Tightened (Aug–Sep 2025)

Gastroparesis claims now need gastric emptying studies; MDL allows NAION and objectively confirmed gastroparesis; Lilly moves to centralize NAION cases.

Court orders & filings detail →

Vision Risk Research Escalates (2025)

Studies report 1.6x RVO risk, 68.6x NAION odds, and NAION incidence of 14.5/100k person-years for semaglutide users.

Read vision risk research summary →

Safety & Label Signals (Late 2025)

Australia TGA orders suicide-risk warning on all GLP-1 labels; Alzheimer’s trials (EVOKE/EVOKE+) fail; CTAD disclosures reinforce missed endpoints.

Safety & regulatory highlights →

Resources & Information

Access important information and resources related to GLP-1 medications and their potential side effects.

Understanding Your Rights

If you or a loved one has experienced serious side effects from GLP-1 medications, you may have legal rights to compensation. Our legal team specializes in pharmaceutical litigation and can help you understand your options.

  • Free Case Evaluation: We offer confidential consultations to assess your case
  • No Upfront Costs: We work on a contingency fee basis - you only pay if we win
  • Nationwide Representation: We serve clients across the United States
  • Experienced Attorneys: Our team has successfully handled pharmaceutical litigation cases

Common Questions About GLP-1 Lawsuits

Q: What types of side effects qualify for a lawsuit?

A: Serious side effects that may qualify include gastroparesis, pancreatitis, gallbladder disease, bowel obstruction, intestinal tissue death, kidney problems, optic nerve damage, and mental health issues.

Q: How long do I have to file a lawsuit?

A: The time limit varies by state, typically 1-3 years from when you discovered or should have discovered your injury. It's important to consult with an attorney as soon as possible.

Q: What compensation might be available?

A: Potential compensation may include medical expenses, lost wages, pain and suffering, and punitive damages in some cases.

Q: Do I need to stop taking my medication?

A: You should consult with your healthcare provider before making any changes to your medication regimen. We can help you understand the risks and benefits.

What You Can Do

Document your symptoms and diagnosis

Keep detailed records of all medical visits, symptoms, and treatments

Gather your medication history

Save all medication bottles, prescriptions, and medical records

Get a free legal evaluation

Understand your rights and potential compensation options

Don't wait. You may be eligible for compensation — but deadlines may apply.

Check Your Eligibility Now

Free Case Evaluation • No Fee Unless We Win

Current Legal Developments

The legal landscape surrounding GLP-1 medications is rapidly evolving:

  • MDL Consolidation: Nearly 3,000 cases consolidated in federal court (MDL 3094)
  • New Jersey Litigation: 21 plaintiffs seeking multicounty litigation for vision loss claims
  • FDA Investigations: Ongoing monitoring of adverse event reports
  • Class Action Potential: Cases may be eligible for class action status

Support Resources

If you're dealing with GLP-1 medication side effects, these resources may help:

  • Medical Support: Connect with specialists who understand GLP-1 complications
  • Patient Communities: Online support groups for those affected
  • Mental Health Resources: Counseling and support for depression and anxiety
  • Financial Assistance: Programs to help with medical expenses
  • Legal Guidance: Our team can help you understand your legal options

About Our Legal Team

We are a North American law firm devoted to holding pharmaceutical companies accountable when their products cause harm. With extensive experience litigating cases involving dangerous drugs, our attorneys are committed to seeking justice for people who have suffered injuries or illnesses after taking GLP-1 medications.

Our legal team understands the complex medical and regulatory issues surrounding weight‑loss and diabetes drugs. We collaborate with medical experts to investigate side effects and build strong cases. If you or a loved one has experienced severe nausea, vomiting, gastrointestinal problems or other complications after taking Ozempic, Wegovy, Mounjaro, Zepbound or similar medications, we are here to help.

Our Commitment

We provide compassionate guidance, thorough case evaluation and vigorous representation to help clients obtain compensation and support for their injuries and medical expenses.

Get Your Free Case Evaluation

If you have been affected by GLP-1 medications, our legal team is ready to help. Take the first step towards justice today.

Start Your Free Case Review →
No fee unless we win your case. Confidential consultation — response within one business day.